Company: RGNT
Filing Date: 2025-05-05
Form Type: F-1/A
Source: 0001213900-25-039589
Chunk: 101

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-05
Form: F-1/A
Chunk 101
---
 in the number of Ordinary Shares we are offering would increase   
 or decrease, respectively, the amount of cash, cash equivalents and short-term deposits, total shareholders’ (deficiency) equity         
 and total capitalization by $0.76 million, assuming the assumed initial public offering price per Ordinary Shares, as set forth on       
 the cover page of this prospectus, remains the same. The pro forma as adjusted information is illustrative only, and we will adjust      
 this information based on the actual initial public offering price and other terms of this offering determined at pricing.               |

<div align='center'>59</div>

The number of the Ordinary
Shares to be issued and outstanding immediately after this offering as shown above assumes that all of the Ordinary Shares offered hereby
are sold, and is based on 3,929,378 Ordinary Shares issued and outstanding as December 31, 2024. This number excludes:

| ● | 79,290 Ordinary Shares issuable upon the exercise of options to consultants under our incentive option plan outstanding as of such date, at an exercise price of $3.97, of which 79,290 were vested as of such date; |

| ● | 465,533 Ordinary Shares                                                                                                             
 issuable upon the exercise of options to chairman of the board of directors to be issued upon the completion of this offering under 
 our incentive option plan (subject to anti-dilution protection), at an exercise price of NIS 0.004;                                 |

| ● | 191,473 Ordinary Shares                                                                                                            
 issuable upon the exercise of options to consultants and certain investors to be issued upon the completion of this offering under 
 our incentive option plan, at an exercise price of NIS 0.004;                                                                      |

| ● | Ordinary Shares underlying                                                                                                            
 warrants issuable to the Bridge Loan lenders to purchase such number of Ordinary Shares equal to two times the respective loan amount 
 of each Bridge Loan lender, based on a price per share equal to 75% of the lowest price per share of the Company’ Ordinary            
 Shares during the first five trading days following the consummation of this offering;                                                |

| ● | Ordinary Shares underlying                                                                                                             
 warrants issuable to the 2024 Loan Agreements lenders to purchase such number of Ordinary Shares equal to two times the respective     
 loan amount of each 2024 Loan Agreements lender, based on a price per share equal to 75% of the lowest price per share of the Company’ 
 Ordinary Shares during the first five trading days following the